It is also a therapeutic option for aldosterone-producing adenomas (APAs), adrenal hyperplasia resistant to medical treatment, and adrenocorticotropic hormone (ACTH)-dependent hypercortisolism, in which the source of ACTH production cannot be removed. Here, POMC is linked to congenital adrenal hyperplasia.